250 mg CK-2017357 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
11	Myasthenia gravis	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 624 /  Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01089010 (ClinicalTrials.gov)	March 2010	16/3/2010	A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Placebo;Drug: 250 mg CK-2017357;Drug: 500 mg CK-2017357	Cytokinetics	NULL	Completed	18 Years	N/A	All	67	Phase 2	United States

11. Myasthenia gravis

---

Clinical trials : 315 /  Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01268280 (ClinicalTrials.gov)	December 2010	28/12/2010	Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis	A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy	Myasthenia Gravis	Drug: Placebo;Drug: 250 mg CK-2017357;Drug: 500 mg CK-2017357	Cytokinetics	National Institute of Neurological Disorders and Stroke (NINDS)	Terminated	18 Years	80 Years	All	32	Phase 2	United States